Data concerning the rate of crossover between the study arms were also collected.
However, there were differences between the study arms in the level of support provided by researchers for the delivery of FootyFirst.
Rates of any bleeding and major bleeding were similar between the study arms in both RE-COVER (Figure 2B) and RE-COVER II [20, 21].
Mixed models repeated measures analysis revealed significant differences between the study arms regarding total PANSS score change favouring n-3 PUFA (p = 0.016; effect size (ES) = 0.29).
In this purpose, we plotted the association between differential glycemic exposure between the study arms and Hazard Ratio for MACE, in randomized controls trials comparing intensive vs. conventional glycemic control.
Efficacy and safety will be compared between the study arms and in patient subgroups including patients with nonsquamous versus squamous tumor histology and patients who received prior bevacizumab treatment.
Measured baseline characteristics did not differ significantly between the study arms.
For randomization of the ZAMSTAR study, we determined the balance between the study arms using each method.
(Table 3) The differences between the study arms were maintained when AIDS-defining events within the first 30 days of randomization were included as endpoints (data not shown).
Reasons for withdrawal from the study are shown in Figure 1; there were no apparent differences between the study arms for adults or children.
Importantly, a difference in clinical outcomes between the study arms was observed in a secondary analysis that evaluated the rates of AIDS progression or death.
